## FACSIMILE COVER SHEET

FEB 2 7 2004

## Licata & Tyrrell P.C.

66 E. Main Street Marlton, New Jersey OFFICIAL

Tel: (856) 810-1515 Fax: (856) 810-1454

E-Mail: JMLicata@licataandtyrrell.com

February 27, 2004

**GROUP: 1635** 

FAX NUMBER: 1-703-872-9306

**ATTORNEY DOCKET NO.: ISPH-0625** 

SERIAL NO.: 10/057,550

FILED: January 25, 2002

NUMBER OF PAGES: 11 (including this sheet)

MESSAGE: Attached is a General Transmittal Letter (in duplicate); four Terminal Disclaimers and Authorization to charge deposit account \$440.00 for Terminal Disclaimer fees (\$110.00 for each Terminal Disclaimer).

## URGENT! PLEASE DELIVER IMMEDIATELY UPON RECEIPT. THANK YOU!

If you have any questions, or did not receive the proper number of pages, or had trouble during transmission, please call 856-810-1515.

## CONFIDENTIALITY NOTICE

The information contained in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ics) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying distribution or taking of any action in reliance on the coments of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the recur of the materials. Thank you.

	TRANSMITTAL LETTER (General - Patent Pending)		Docket No. ISPH-0625
In Re Application Of: 18r	ett P. Monia		
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner  James Schultz	Group Art Unit 1635
Title: ANTISENSE OLI	GONUCLEOTIDE MODULATI	ON BY RAF GENE EXPRESS	SION
•	TO THE COMMISSI	ONER FOR PATENTS:	
Transmitted herewith is: Four Terminal Disclaim	ners		
as described belov ⊠ Charge th ⊠ Credit any	s required. ount of is atta reby authorized to charge and c	* * ***	50-1619
Jane Massey Licata Reg. No. 32,257 Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454	gnature	on first class mail und Commissioner for 223,13-1450.	document and fee is being deposited with the U.S. Postal Service as der 37 C.F.R. 1.8 and is addressed to the Palents, P.O. Box 1450, Alexandria, VA
<u></u>		Typed or Printed	Name of Person Mailing Correspondence

		RECEIVED	
	TRANSMITTAL LETTER	CENTRAL FAX CHITER	Docket No.
(	(General - Patent Pending)	. <u>FEB 2 7 2004</u>	ISPH-0625
In Re Application Of: 33r	ett P. Monia	OFFI	
Serial No.	Filing Date	Examiner	Group Art Unit
10/057,550	January 25, 2002	James Schultz	1635
Title: ANTISENSE OLIC	GONUCLEOTIDE MODULATION	ON BY RAF GENE EXPRESSION	
			0
	TO THE COMMISSION	ONER FOR PATENTS:	
Transmitted herewith is:			
Four Terminal Disclaime	ers	, X	E
	•		
in the chart identified age	Vication	•	•
in the above identified app			
<ul><li>☐ No additional fee is</li><li>☐ A check in the amount</li></ul>	·	L_ 1	
	unt of is attac by authorized to charge and cre		50-1619
as described below.			
	amount of \$440.00 coverpayment.		
	additional fee required.		
	*.		
Schoon Cor		Dated: February 27, 2004	
Sign	ature	•	
Jane Massey Licata Reg. No. 32,257			
Licata & Tyrrell P.C.		I certify that this docum	ent and fee is being deposited
66 E. Main Street Marlton, NJ 08053		ОП	with the U.S. Postal Service as F.R. 1.8 and is addressed to the
Cel: 856-810-1515 Cax: 856-810-1454			P.O. Box 1450, Alexandria, VA
. ww. 070-010-1117.4		22313-1450.	
		Signature of Person	Mailing Correspondence
		,	
0:		Typed or Printed Name of	Person Mailing Correspondence
·	_ <u></u>		

				D. Lot N.
CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)  Applicant(s): Brett P. Monia  Docket No.  ISPH-0625				
Application 2				O-4 in A-411 is
Şerial No.	Filing Date	Examiner		Group Art Unit
10/057,550	January 25, 2002	James Schultz		1635
Invention: ANTISENSE	COLIGONUCLEOTIDE MODU	LATION BY RAF GENE EXI	PRESS	ION
I hereby certify that this	•	Terminal Disclaimer		
		(Identify type of correspondence)	No 5	782 971 N2N6 N
is being facsimile transn	nitted to the United States Paten	t and Trademark Office (Fax.	NQ. 7	03-8/2-9300 )
on February 2	27, 2004			
(Date)				
		Jane Masse	y Lica	ta
		(Typed or Printed Name of Pet	rson Sigi	ning Certificate)
		Sand derete		
		Janay Just	re)	
÷				
		•		
	Made. Daub and an area of the	area the areas on obtaining of meating		
	ivote: Lach paper must n	ave its own certificate of mailing.		
	•			
*	*			
	•			
	•			
				,

→ PTOBF

Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent  Docket No. ISPH-0625					
In Re Application Of: Brett P. Monia					
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635		
Invention: ANTISENSI	E OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EXI	PRESSION		
Owner of Record: Isis I	Phármaceuticals, Inc.	·	· .		
	TO THE COMMISS	IONER FOR PATENTS:			
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,410,518. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all'claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. Por submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false.					
statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.  2.   The undersigned is an attorney of record.					
Typed  Terminal disclaim  PTO suggested w	Signature Massey Licata For Printed Name er fee under 37 C.F.R. 1.20(d) inclu ording for terminal disclaimer was u	inchanged.			

→ PTOBF

CODE COLUMN CE	TRANSMISSION BY FACS	SIMILE (37 CER 1.8)	Docket No.
Applicant(s): Brett P. M.		JI.III. (37 OF XL 110)	ISPH-0625
Serial No.	Filing Date	Examiner	Group Art Unit
10/057,550	January 25, 2002	James Schultz	1635
Invention: ANTISENSE	OLIGONUCLEOTIDE MODUL	LATION BY RAF GENE EXI	PRESSION
	·		
	,		
4			
i hereby certify that this		Terminal Disclaimer (Identify type of correspondence)	
is being facsimile transm	nitted to the United States Patent	and Trademark Office (Fax.	No. 703-872-9306 )
on February 2		•	· ·
(Date)			
		Jane Masse (Typed or Printed Name of Pea	ey Licata rson Signing Certificate)
		Signatu	irc)
0 ( 0	•		
	Note: Each paper must b	ave its own certificate of mailing.	
	())		
-		•	•.
8.			
,			
		÷.	
ik.			
T			

Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent			Docket No. ISPH-0625		
In Re Application Of: Bu	In Re Application Of: Brett P. Monia				
Serial No.	Filing Date	Examiner	Group Art Unit		
10/057,550	Јапиагу 25, 2002	James Schultz	1635		
Invention: ANTISENSE	OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EXI	PRESSION		
			,		
Owner of Record: Isis P	harmaceuticals, Inc.				
· · · · · · · · · · · · · · · · · · ·					
	TO THE COMMISS	IONER FOR PATENTS:			
provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,358,932. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.					
Check either box 1 or 2 below, if appropriate.					
	1.  For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.				
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.					
2. The undersigned is an attorney of record.					
Dated: February 27, 2004					
Jane Massey Licata					
Typed or Printed Name Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.					
PTO suggested wording for terminal disclaimer was unchanged. Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.					
	<u> </u>				

OPPOTEICATE OF	TRANSMISSION BY FACS	SIMILE (37 CFR 1.8)	Docket No.
Applicant(s): Brett P. M	onia	(4, 222)	ISPH-0625
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635
Invention: ANTISENSE	COLIGONUCLEOTIDE MODUI	LATION BY RAF GENE EXI	PRESSION
·		a.	
	<u> </u>	12	
•			
			•
I hereby certify that this		Terminal Disclaimer	
is being facsimile transn	nitted to the United States Patent	(Identify type of correspondence) and Trademark Office (Fax.	No. 703-872-9306 )
on February 2			
(Date)			
·		Jane Masso (Typed or Printed Nume of Per	ey Licata
		(Typen of France Italia of Te	:
	-	Ja anny ed (Signatu	nre)
ē			
	Note: Each paper must be	ave its own certificate of mailing.	
1			
			• • •

Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent					
In Re Application Of: Brett P. Monia					
Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635			
E OLIGONUCLEOTIDE MODUI	LATION OF RAF GENE EXPI	RESSION			
Pharmaceuticals, Inc.					
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5,919,773. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is relisated, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.  Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issued thereon					
Signature  e Massey Licata  d or Printed Name  ner fee under 37 C.F.R. 1.20(d) inclu- yording for terminal disclaimer was u	inchanged.				
	Filing Date January 25, 2002  E OLIGONUCLEOTIDE MODULE  TO THE COMMISS  fied owner of record of a 100 per full statutory term defined in 35 U No. 5,919,773. The owner her full statutory term defined in 35 U not application and is binding upon the field of the expiration date of the full statutory term as presently shortened by any terminal disclaimer, in and invalid by a court of competent is all claims cancelled by a reexamination to the expiration date of the full statutory term as presently shortened by 1 or 2 below, if appropriate.  On behalf of an organization (e.g., do to act on behalf of the organization in that all statements made herein believed to be true; and further the organization is an attorney of record.  Signature  Massey Licata for Printed Name for the under 37 C.F.R. 1.20(d) inclusiverding for terminal disclaimer was be considered as a second of the conditions of	Filing Date January 25, 2002  For the Commissioner For Patents  TO THE COMMISSIONER FOR PATENTS:  The downer of record of a 100 percent interest in the instant app full statutory term defined in 35 U.S.C. 164 to 156 and 173, as and during such period that it and the prior patent are commonly owned application and is binding upon the grantee, its successors and/or sind to the expiration date of the full statutory term defined in 35 U.S.C. 164 to 156 and 173, as and during such period that it and the prior patent are commonly owned application and is binding upon the grantee, its successors and/or sind to the expiration date of the full statutory term as defined in 35 U.S.C. 164 to 156 and 173, as and to the expiration date of the full statutory term as defined in 35 U.S.C. 164 to 156 and 173, as and to the expiration and is binding upon the grantee, its successors and/or sind to the expiration date of the full statutory term as defined in 35 U.S.C. 164 to 156 and 173, as and to the expiration and is binding upon the grantee, its successors and/or sind to the expiration fate of the sun that it later expires for and invalid by a court of competent jurisdiction, is statutorily disclaims sail claims cancelled by a reexamination certificate, is relssued, or the sun that all statements made herein of my own knowledge are true that all statements made herein of my own knowledge are true to a made are punishable by fine or imprisonment, or both, under Se a willful false statements may jeopardize the validity of the application is an attorney of record.  Dated: February 27, 200.  Signature  Massey Licata			

CERTIFICATE OF Applicant(s): Brett P. M	TRANSMISSION BY FACS	SIMILE (37 CFR 1.8)	Docket No. ISPH-0625
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner James Schultz	Group Art Unit 1635
Invention: ANTISENSE	OLIGONUCLEOTIDE MODUI	LATION BY RAF GENE EXP	ression
	-	*	•
I hereby certify that this		Terminal Disclaimer (Idently) type of correspondence)	No. 703-877-9306 )
on February 2	<del></del>	rand Frademark Office (Fax.)	NO, 703-672-7300 )
,	· _ ·	Jane Masse (Typed or Printed Name of Per	y Licata
	* · <del></del>	Schoony locks (Signalu	
		·	· ,
*	Note: Each paper must h	ave its own certificate of mailing.	
, ,			
	•		
3	•		
		_	·

Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent  Docket No. ISPH-0625					
In Re Application Of: B	In Re Application Of: Brett P. Monia				
Serial No. 10/057,550	Filing Date January 25, 2002	Examiner  James Schultz	Group Art Unit 1635		
Invention: ANTISENSE	OLIGONUCLEOTIDE MODU	LATION OF RAF GENE EX	PRESSION		
	·	, <u> </u>			
Owner of Record: Isis P	harmaceuticals, Inc.		*		
	TO THE COMMISS	IONER FOR PATENTS:	·		
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5,744,362. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.					
1.   For submissions o	Check either box 1 or 2 below, if appropriate.  1.   For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.				
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.					
2. The undersigned is an attorney of record.					
Dated: February 27, 2004 Signature					
Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.  PTO suggested wording for terminal disclaimer was unchanged.  Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.					